Abstract Number: 1039 • 2018 ACR/ARHP Annual Meeting
Tenofovir Induces Osteopenia and Dipyridamole, an Inhibitor of the Ent-1 Nucleoside Transporter, Reverses the Osteopenic Effect of Tenofovir In Vivo
Background/Purpose: Osteopenia and fragility fractures have been associated with HIV infection. Tenofovir, one of the most commonly used antivirals in HIV, also leads to increases…Abstract Number: 2808 • 2018 ACR/ARHP Annual Meeting
T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
Background/Purpose: BMD is a strong predictor of fracture risk in untreated patients. Recent evidence suggests that BMD achieved during treatment also reflects fracture risk; thus,…Abstract Number: 337 • 2016 ACR/ARHP Annual Meeting
Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability
Background/Purpose: Denosumab is approved for treating postmenopausal women with osteoporosis at high risk for fracture. The placebo-controlled FREEDOM trial and its active-treatment Extension investigated the…Abstract Number: 1023 • 2016 ACR/ARHP Annual Meeting
Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis
Background/Purpose: Romosozumab (Romo) is an investigational bone-forming monoclonal antibody that binds sclerostin and has a dual effect, increasing bone formation and decreasing bone resorption. Here,…Abstract Number: 1024 • 2016 ACR/ARHP Annual Meeting
Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial
Background/Purpose: STRUCTURE was a phase 3, open-label study evaluating the effect of romosozumab or teriparatide for 12 months in women with postmenopausal osteoporosis transitioning from…Abstract Number: 1028 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from a Phase 3 Placebo-Controlled Study of Denosumab and Its Open-Label Extension
Background/Purpose: Denosumab (DMAb) treatment has been shown to decrease fracture (Fx) risk. Unlike bisphosphonates, DMAb is a monoclonal antibody against RANKL. Discontinuation is characterized by…Abstract Number: 321 • 2016 ACR/ARHP Annual Meeting
Results of a Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Romosozumab in Men with Osteoporosis
Background/Purpose: Treatment with romosozumab (Romo) has been shown to rapidly increase BMD in postmenopausal women with low BMD through a dual effect on bone, increasing…Abstract Number: 323 • 2016 ACR/ARHP Annual Meeting
Effect of 10 Years of Denosumab Treatment on Bone Histology and Histomorphometry in the Freedom Extension Study
Background/Purpose: Denosumab (DMAb) has been associated with low incidence of spine and non-spine, including hip, fractures through 10 years of treatment (Bone ASBMR 2015). Questions…Abstract Number: 336 • 2016 ACR/ARHP Annual Meeting
The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab
Background/Purpose: Osteoporosis is a common, progressive condition leading to increased bone fragility and susceptibility to fracture. Although osteoporosis therapy decreases fracture risk, fractures while on…Abstract Number: 125 • 2015 ACR/ARHP Annual Meeting
Implementation of a Bone Health Team Markedly Improves Osteoporosis Screening, Diagnosis and Treatment Initiation Rates Compared to Standard Primary Care Practice
Background/Purpose: Despite the availability of effective therapies for fracture prevention, osteoporosis screening and treatment rates in practice are low. Fracture liaison services are effective at…Abstract Number: 2255 • 2014 ACR/ARHP Annual Meeting
Vertebral Cortical Bone Mass and Structure Significantly Improved with Romosozumab Compared with Teriparatide: HR-QCT Analyses of Postmenopausal Women with Low BMD from a Phase 2 Study
Background/Purpose : Understanding the effect of therapies in the vertebral compartments is relevant to bone biology and clinical practice. We developed an improved technique using…Abstract Number: 234 • 2014 ACR/ARHP Annual Meeting
The Decrease in Prescription of Anti-Osteoporotic Drugs Has No Impact on Hip Fracture Incidence
Background/Purpose Controversies exist about the change in hip fracture incidence among countries. In France, we previously showed that the incidence of hip fractures decreased in…Abstract Number: 49 • 2014 ACR/ARHP Annual Meeting
Long-Term Oral Bisphosphonate Use for Osteoporosis Among Older Women – US and Canadian Perspective
Background/Purpose: Bisphosphonates (BPs) have been widely used for the treatment and prevention of osteoporosis for two decades. Although new parenteral preparations have been introduced, oral…Abstract Number: 48 • 2014 ACR/ARHP Annual Meeting
Osteoporotic Women at High Risk for Fractures Despite Two Years of Oral Bisphosphonate Therapy: Analysis Using the Canadian Multicentre Osteoporosis Study
Background/Purpose Individuals with osteoporosis (OP) have an increased susceptibility to fractures. Prevention and treatment of postmenopausal OP is critical to decreasing the risk of non-traumatic…Abstract Number: 1219 • 2013 ACR/ARHP Annual Meeting
Phase 3 Fracture Trial Of Odanacatib For Osteoporosis – Baseline Characteristics and Study Design
Background/Purpose: Odanacatib is a selective and reversible inhibitor of cathepsin K; a collagenase secreted by osteoclasts, and is currently being evaluated for the treatment of…